changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
Certain BTG products may not be available within the chosen location and indications may differ from your country's approved use.
For Medical questions regarding any BTG products, please contact email@example.com
An open-label, prospective, multicenter, randomized, Phase III clinical trial evaluating yttrium-90 transarterial radioembolisation (TheraSphere™) versus the standard of care (sorafenib) for the treatment of advanced hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT).29,30
Standard-of-care therapy: sorafenib
To assess efficacy and safety of TheraSphere™ in comparison to sorafenib therapy in the treatment of patients with PVT associated with unresectable HCC.
Primary: Overall survival
Secondary:Time to progression, time to worsening portal vein thrombosis, response rate, time to symptomatic progression, quality of life (FACT-hep), safety
Please visit the THERASPHERE TRIALS WEBSITE for more details